Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) released its earnings results on Thursday. The biotechnology company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02, Briefing.com reports. Progenics Pharmaceuticals had a negative net margin of 445.81% and a negative return on equity of 67.61%. The company had revenue of $2.70 million for the quarter, compared to analysts’ expectations of $3.58 million. During the same quarter last year, the business earned $0.52 EPS. The firm’s revenue was down 95.0% compared to the same quarter last year.

Progenics Pharmaceuticals (PGNX) traded up $0.28 during trading on Friday, hitting $6.14. 755,738 shares of the stock traded hands, compared to its average volume of 916,353.

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/11/03/progenics-pharmaceuticals-inc-pgnx-issues-earnings-results.html.

PGNX has been the topic of a number of recent analyst reports. Cantor Fitzgerald restated a “buy” rating and set a $15.00 target price on shares of Progenics Pharmaceuticals in a research note on Thursday. Aegis reiterated a “buy” rating and set a $14.00 price objective on shares of Progenics Pharmaceuticals in a research report on Tuesday, August 22nd. ValuEngine upgraded shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, September 18th. Zacks Investment Research cut shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 18th. Finally, BidaskClub cut shares of Progenics Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 11th. Three research analysts have rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $13.20.

Progenics Pharmaceuticals Company Profile

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Earnings History for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.